Eagle Lands On COVID-Hit Acacia
Acquires UK Company For Under €95m
Acacia launched two hospital drugs – Barhemsys and Byfavo – in the US during COVID but failed to overcome the physical access limitations caused by the pandemic. Eagle of the US thinks it can tap into a potentially lucrative market and is buying the beleaguered biotech.
You may also be interested in...
Saniona and Bone Therapeutics are the latest companies on the continent to be forced into drastic restructuring, shedding jobs and research projects to preserve rapidly dwindling cash piles.
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Having secured FDA approval, the UK's Acacia Pharma will market Byfavo, the first new product in the sedation space in decades, which was licensed from Italy's Cosmo and developed by Germany's Paion.